Rubitecan

Drug Profile

Rubitecan

Alternative Names: 9-NC; 9-Nitro-20(S)-camptothecin; 9-Nitro-camptothecin; Partaject Orathecin; Partaject rubitecan; RFS 2000

Latest Information Update: 14 Feb 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The Stehlin Foundation for Cancer Research
  • Developer SuperGen
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV infections; Pancreatic cancer

Highest Development Phases

  • Discontinued Breast cancer; Chronic myelomonocytic leukaemia; Colorectal cancer; HIV infections; Leukaemia; Lung cancer; Myelodysplastic syndromes; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 26 Apr 2006 Interim results from a US-based phase II clinical trial in patients with primary advanced Pancreatic cancer have been added to the Cancer therapeutic trials section
  • 24 Jan 2006 SuperGen has withdrawn its MAA from the EMEA for rubitecan for the treatment of Pancreatic cancer
  • 20 Jan 2006 Phase-III clinical trials in Pancreatic cancer in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top